



EXPRESS MAIL NO. EV335608545US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William L. Hunter and Lindsay S. Machan
Application No. : 10/671,327
Filed : September 25, 2003
For : COMPOSITIONS AND METHODS FOR TREATING OR
PREVENTING DISEASES OF BODY PASSAGEWAYS

Art Unit : 1614
Docket No. : 110129.405C3
Date : July 8, 2004

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/933,652, filed August 20, 2001; which is a continuation 08/653,207, filed May 24, 1996. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.


As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such

reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Jeffrey C. Pepe, Ph.D.
Registration No. 46,985

JCP:ljt


Enclosures:

Postcard

Form PTO-1449 (27 Sheets)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

473711

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	2,286,254	02/15/94	Shapland et al.	604	21	
AB	3,312,753	04/04/67	Bailey et al.	260	823	
AC	3,797,485	03/19/74	Urquhart	128	213	
AD	4,357,312	11/02/82	Hsieh et al.	424	15	
AE	4,526,938	07/02/85	Churchill et al.	525	415	
AF	4,531,936	07/30/85	Gordon	604	49	
AG	4,591,496	05/27/86	Cohen et al.	424	15	
AH	4,663,308	5/5/87	Saffran et al.	514	3	
AI	4,745,160	05/17/88	Churchill et al.	525	415	
AJ	4,768,523	09/06/88	Cahalan et al.	128	785	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	CA 2,113,683	07/19/95	Canada		
	AL	EP 516 749 B1	12/09/92	EPO		
	AM	EP 531 938 B1	03/17/93	EPO		
	AN	EP 547 530 A1	06/23/93	EPO		
	AO	EP 584 001 A1	07/29/93	EPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AP	Adams et al., "Taxol: A History of Pharmaceutical Development and Current Pharmaceutical Concerns," <i>Monogr. Natl. Cancer Inst.</i> 15: 141-147, 1993.
AQ	Ajani et al., "Activity of Taxol in Patients With Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus," <i>J. Natl. Cancer Inst.</i> 86: 1086-1091, 1994.
AR	Ali et al., "Mechanisms of polymer degradation in implantable devices," <i>Biomaterials</i> 14(9): 648-656, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	4,808,402	02/28/89	Leibovich et al.	424	423	
	BB	4,814,470	03/21/89	Colin et al.	514	449	
	BC	4,863,735	09/05/89	Kohn et al.	424	422	
	BD	4,882,168	11/21/89	Casey et al.	424	468	
	BE	4,906,474	03/06/90	Langer et al.	424	428	
	BF	4,942,184	07/17/90	Haugwitz et al.	514	449	
	BG	4,947,840	08/14/90	Yannas et al.	128	156	
	BH	4,987,071	01/22/91	Cech et al.	435	91	
	BI	4,989,601	02/05/91	Marchosky et al.	128	399	
	BJ	5,002,572	03/26/91	Picha	623	11	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BK	EP 623 354 A1	11/09/94	EPO		
	BL	EP 627 226 A1	12/07/94	EPO		
	BM	EP 639 380 A1	02/22/95	EPO		
	BN	EP 645 145 A2	03/29/95	EPO		
	BO	EP 689 807 A2	01/03/96	EPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BP	Alkan-Onyuksel et al., "A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol," <i>Pharmaceutical Research</i> 11(2): 206-212, 1994.
	BQ	Anonymous, "Taxol," <i>The Lancet</i> 339: 1447-1448, 1992.
	BR	Anseth et al., "Mechanical properties of hydrogels and their experimental determination," <i>Biomaterials</i> 17: 1647-1657, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	5,019,096	05/28/91	Fox, Jr. et al.	623	1	
	CB	5,032,572	7/16/91	Saffran et al.	514	3	
	CC	5,049,132	09/17/91	Shaffer et al.	604	101	
	CD	5,053,048	10/01/91	Pinchuk	623	1	
	CE	5,057,606	10/15/91	Garbe	536	54	
	CF	5,059,166	10/22/91	Fischell et al.	600	3	
	CG	5,089,606	02/18/92	Cole et al.	536	54	
	CH	5,100,668	3/31/92	Edelman et al.	424	422	
	CI	5,126,141	06/30/92	Henry	424	423	
	CJ	5,145,684	09/08/92	Liversidge et al.	424	489	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CK	EP 704 222 A1	04/03/96	EPO		
	CL	EP 716 836 A1	06/19/96	EPO		
	CM	EP 717 041 A1	06/19/96	EPO		
	CN	WO 90/13332	11/15/90	WIPO		
	CO	WO 91/07154	05/03/91	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CP	Bae et al., " "On-Off" thermocontrol of solute transport. I. Temperature dependence of swelling of N-isopropylacrylamide networks modified with hydrophobic components in water," <i>Pharmaceutical Research</i> 8(4): 531-537, 1991.
	CQ	Bartoli et al., "In vitro and in vivo antitumoral activity of free, and encapsulated taxol," <i>J. Microencapsulation</i> 7(2): 191-197, 1990.
	CR	Belcheva et al., "Crosslinked poly (ethylene oxide) for drug release systems," <i>Macromol. Symp.</i> 103: 193-211, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA	5,157,049	10/20/92	Haugwitz et al.	514	449	
	DB	5,171,217	12/15/92	March et al.	604	53	
	DC	5,171,262	12/15/92	MacGregor	623	1	
	DD	5,179,174	01/12/93	Elton	525	409	
	DE	5,213,580	05/25/93	Slepian et al.	623	1	
	DF	5,225,347	07/06/93	Goldberg et al.	435	320.1	
	DG	5,254,678	10/19/93	Haseloff et al.	536	23.2	
	DH	5,258,042	11/02/93	Mehta	623	66	
	DI	5,262,409	11/16/93	Margolis et al.	514	183	
	DJ	5,278,324	01/11/94	Kingston et al.	549	510	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DK	WO 92/15282	9/17/92	WIPO		
	DL	WO 93/18751	09/30/93	WIPO		
	DM	WO 93/19739	10/14/93	WIPO		
	DN	WO 93/24476	12/09/93	WIPO		
	DO	WO 94/00156	01/06/94	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DP	Berrabah et al., "GC-MS determination of phenobarbitone entrapped in poly-ε-caprolactone nanocapsules," <i>Journal of Pharmaceutical & Biomedical Analysis</i> 12(3): 373-378, 1994.
	DQ	Bissett and Kaye, "Taxol and Taxotere-Current Status and Future Prospects," <i>Eur. J. Cancer</i> 29A(9): 1228-1231, 1993.
	DR	Blanco-Fuente et al., "Tanned leather: a good model for determining hydrogels bioadhesion," <i>International Journal of Pharmaceutics</i> 138: 103-112, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA	5,284,868	02/08/94	Dell et al.	514	454	
	EB	5,288,502	02/22/94	McGinity et al.	424	484	
	EC	5,288,503	02/22/94	Wood et al.	424	497	
	ED	5,290,585	03/01/94	Elton	427	2	
	EE	5,301,664	04/12/94	Sievers et al.	128	200.23	
	EF	5,302,397	04/12/94	Amsden et al.	424	473	
	EG	5,304,121	04/19/94	Sahatjian	604	53	
	EH	5,304,377	04/19/94	Yamada et al.	424	426	
	EI	5,314,444	05/24/94	Gianturco	606	195	
	EJ	5,314,688	05/24/94	Kauffman et al.	424	423	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	EK	WO 94/02595	02/03/93	WIPO		
	EL	WO 94/14415	07/07/94	WIPO		
	EM	WO 94/20089	09/15/94	WIPO		
	EN	WO 94/21308	09/29/94	WIPO		
	EO	WO 94/21309	09/29/94	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	EP	Brahn et al., "Regression Of Collagen-Induced Arthritis With Taxol, A Microtubule Stabilizer," <i>Arthritis & Rheumatism</i> 37(6): 839-845, 1994.
	EQ	Brem and Langer, "Polymer-Based Drug Delivery to the Brain," <i>Science and Medicine July/August</i> : 52-61, 1996.
	ER	Bromberg, "Crosslinked poly (ethylene glycol) networks as reservoirs for protein delivery," <i>Journal of Applied Polymer Science</i> 59: 459-466, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA	5,318,780	06/07/94	Viegas et al.	424	427	
	FB	5,324,519	06/28/94	Dunn et al.	424	426	
	FC	5,328,471	07/12/94	Slepian	604	101	
	FD	5,330,768	07/19/94	Park et al.	424	501	
	FE	5,340,849	08/23/94	Dunn et al.	523	113	
	FF	5,342,348	08/30/94	Kaplan	604	891.1	
	FG	5,362,831	11/08/94	Mongelli et al.	526	304	
	FH	5,383,928	01/24/95	Scott et al.	623	1	
	FI	5,391,164	02/21/95	Giampapa	604	891.1	
	FJ	5,399,363	03/21/95	Liversidge et al.	424	490	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	FK	WO 94/25020	11/10/94	WIPO		
	FL	WO 94/26254	11/24/94	WIPO		
	FM	WO 94/26728	11/24/94	WIPO		
	FN	WO 95/03036	02/02/95	WIPO		
	FO	WO 95/03795	02/09/95	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	FP	Brown et al., in <i>Comprehensive Polymer Science: The Synthesis, characterization, reactions and applications of polymers. Vol 2-Polymer Properties</i> , Allen et al (eds.), Pergamon Press, Oxford, 1989, pp. 155-198.
	FQ	Bruin et al., "Biodegradable lysine diisocyanate-based poly(glycolide-co-ε-caprolactone)-urethane network in artificial skin," <i>Biomaterials</i> 11: 291-295, 1990.
	FR	Burt et al., "Controlled delivery of taxol from microspheres composed of a blend of ethylene-vinyl acetate copolymer and poly (d,l-lactic acid)," <i>Cancer Letters</i> 88: 73-79, 1995

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA	5,399,666	03/21/95	Ford	528	354	
	GB	5,405,919	04/11/95	Keefer et al.	525	377	
	GC	5,407,683	04/18/95	Shively	424	439	
	GD	5,410,016	04/25/95	Hubbell et al.	528	354	
	GE	5,415,869	05/16/95	Straubinger et al.	424	450	
	GF	5,419,760	05/30/95	Narciso, Jr.	604	8	
	GG	5,421,826	06/06/95	Crocker et al.	604	53	
	GH	5,424,073	06/13/95	Rahman et al.	424	450	
	GI	5,434,241	07/18/95	Kim et al.	528	354	
	GJ	5,438,072	08/01/95	Bobee et al.	514	449	
	GK	5,439,446	08/08/95	Barry	604	96	
	GL	5,439,686	08/08/95	Desai et al.	424	451	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	GM	WO 95/20582	08/03/95	WIPO		
	GN	WO 96/03984	02/15/96	WIPO		
	GO	WO 96/25176	08/22/96	WIPO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GP	Calvo et al., "Study of the mechanisms of interaction of poly(ϵ -caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy," <i>International Journal of Pharmaceutics</i> 103: 283-291, 1994.
	GQ	Cascone et al., "Collagen and hyaluronic acid based polymeric blends as drug delivery systems for the release of physiological concentrations of growth hormone," <i>Journal of Materials Science Materials in Medicine</i> 5: 770-774, 1994.
	GR	Cerrai et al., "Block copolymers of L-lactide and poly (ethylene glycol) for biomedical applications," <i>Journal of Materials Science: Materials in Medicine</i> 5: 308-313, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327**INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA	5,441,947	08/15/95	Dodge et al.	514	179	
	HB	5,443,508	08/22/95	Giampapa	623	11	
	HC	5,446,070	08/29/95	Mantelle	514	772.6	
	HD	5,447,724	09/05/95	Helmus et al.	424	426	
	HE	5,449,513	09/12/95	Yokoyama et al.	424	78.08	
	HF	5,455,027	10/03/95	Zalipsky et al.	424	78.17	
	HG	5,455,039	10/03/95	Edelman et al.	424	422	
	HH	5,455,046	10/03/95	Baichwal	424	457	
	HI	5,457,113	10/10/95	Cullinam et al.	514	319	
	HJ	5,461,140	10/24/95	Heller et al.	528	425	
	HK	5,462,523	10/31/95	Samson et al.	604	30	
	HL	5,462,751	10/31/95	Kossovsky et al.	424	494	
	HM	5,462,937	10/31/95	Cullingham et al.	514	212	
	HN	5,464,450	11/07/95	Buscemi et al.	623	6	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	HO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	HP	Chen et al., "Novel hydrogels of a temperature-sensitive pluronic® grafted to a bioadhesive polyacrylic acid backbone for vaginal drug delivery," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mate.</i> 22: 167-168, 1995.
	HQ	Chun and Kim, "A novel hydrogel-dispersed composite membrane of poly (N-isopropylacrylamide) in a gelatin matrix and its thermally actuated permeation of f4-acetamidophen," <i>Journal of Controlled Release</i> 38:39-47, 1996.
	HR	Coffin and McGinity, "17. Physical and Chemical Stability of Aqueous Colloidal Dispersions of Poly (DL-Lactide and Poly (ε-Prolactone)," <i>Drug Targeting Delivery 1</i> : 197-214, 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA	5,464,650	11/07/95	Berg et al.	427	2.30	
	IB	5,464,932	11/07/95	Allcock et al.	528	399	
	IC	5,466,262	11/14/95	Saffran	623	16	
	ID	5,470,307	11/28/95	Lindall	604	20	
	IE	5,473,055	12/05/95	Mongelli et al.	530	329	
	IF	5,476,909	12/19/95	Kim et al.	525	408	
	IG	5,494,683	02/27/96	Liversidge et al.	424	490	
	IH	5,496,581	03/05/96	Yianni et al.	427	2.12	
	II	5,496,846	03/05/96	Wilson et al.	514	449	
	IJ	5,502,158	03/26/96	Sinclair et al.	528	354	
	IK	5,512,055	04/30/96	Domb et al.	604	265	
	IL	5,512,297	04/30/97	Baichwal	424	451	
	IM	5,514,092	05/07/96	Forman et al.	604	101	
	IN	5,514,379	05/07/96	Weissleder	424	426	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	IO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	IP	Cohn and Younes, "Compositional and structural analysis of PELA biodegradable block copolymers degrading under <i>in vitro</i> conditions," <i>Biomaterials</i> 10: 466-474, 1989.
	IQ	Cornejo-Bravo et al., "Kinetics of drug release from hydrophobic polybasic gels: effect of buffer acidity," <i>Journal of Controlled Release</i> 33: 223-229, 1995.
	IR	Cserháti, "Interaction of some anticancer drugs with carboxymethyl- β -cyclodextrin," <i>International Journal of Pharmaceuticals</i> 124: 205-211, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA	5,514,380	05/07/96	Song et al.	424	426	
	JB	5,516,522	05/14/96	Peyman et al.	424	426	
	JC	5,519,042	05/21/96	Morris et al.	514	378	
	JD	5,523,092	06/04/96	Hanson et al.	424	423	
	JE	5,525,356	06/11/96	Jevne et al.	424	484	
	JF	5,527,532	06/18/96	Edelman et al.	424	422	
	JG	5,531,716	07/02/96	Luzio et al.	604	265	
	JH	5,531,735	07/02/96	Thompson	604	891.1	
	JI	5,532,388	07/02/96	Bouchard et al.	549	510	
	JJ	5,534,287	07/09/96	Lukic	427	2.25	
	JK	5,534,449	07/09/96	Dennison et al.	437	34	
	JL	5,536,794	07/16/96	Yezrielev et al.	525	443	
	JM	5,538,504	07/23/96	Linden et al.	604	53	
	JN	5,540,912	07/30/96	Roorda et al.	424	422	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	JO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	JP	De Scheerder et al., "Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries," <i>Atherosclerosis</i> 114: 105-114, 1995.
	JQ	Dinarvand and D'Emanuele, "The use of thermoresponsive hydrogels for on-off release of molecules," <i>Journal of Controlled Release</i> 36: 221-227, 1995.
	JR	Dolan et al., "Biodistribution of O ⁶ -benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL," <i>Cancer Chemother Pharmacol</i> 35: 121-126, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	KA	5,540,928	7/30/96	Edelman et al.	424	422	
	KB	5,543,218	08/06/96	Bennett et al.	428	375	
	KC	5,545,208	08/13/96	Wolff et al.	623	1	
	KD	5,545,569	08/13/96	Grainger et al.	436	518	
	KE	5,548,035	08/20/96	Kim et al.	525	408	
	KF	5,554,147	09/10/96	Batich et al.	604	890.1	
	KG	5,554,182	09/10/96	Dinh et al.	623	1	
	KH	5,554,387	09/10/96	Baichwal	424	488	
	KI	5,556,635	09/17/96	Istin et al.	424	448	
	KJ	5,556,877	09/17/96	Bouchard et al.	514	449	
	KK	5,556,878	09/17/96	Kelly et al.	514	449	
	KL	5,558,642	09/24/96	Schweich, Jr. et al.	604	96	
	KM	5,560,933	10/01/96	Soon-Shiong et al.	424	489	
	KN	5,562,922	10/08/96	Lambert	424	486	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	KO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	KP	Dong and Hoffman, "A novel approach for preparation of pH-sensitive hydrogels for enteric drug delivery," <i>Journal of Controlled Release</i> 15: 141-152, 1991.
	KQ	Dong et al., "Controlled release of amylase from a thermal and pH-sensitive, macroporous hydrogels," <i>Journal of Controlled Release</i> 19: 171-178, 1992.
	KR	Dordunoo et al., "Release of taxol from poly(ϵ -caprolactone) pastes: effect of water-soluble additives," <i>Journal of Controlled Release</i> 44: 87-94, 1997.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	LA	5,565,432	10/15/96	Novak et al.	514	25	
	LB	5,565,523	10/15/96	Chen et al.	525	176	
	LC	5,567,435	10/22/96	Hubbell et al.	424	426	
	LD	5,569,197	10/29/96	Helmus et al.	604	96	
	LE	5,569,720	10/29/96	Mongelli et al.	525	329.4	
	LF	5,573,781	11/12/96	Brown et al.	424	484	
	LG	5,573,934	11/12/96	Hubbell et al.	435	177	
	LH	5,575,815	11/19/96	Slepian et al.	623	1	
	LI	5,576,072	11/19/96	Hostettler et al.	427	532	
	LJ	5,578,661	11/26/96	Fox et al.	524	027	
	LK	5,580,575	12/03/96	Unger et al.	424	450	
	LL	5,580,899	12/03/96	Mayhew et al.	514	449	
	LM	5,582,591	12/10/96	Cheikh	604	51	
	LN	5,585,348	12/17/96	Crain et al.	514	12	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	LO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	LP	Dordunoo et al., "Taxol encapsulation in poly(ε-caprolactone) microspheres," <i>Cancer Chemother Pharmacol</i> 36: 279-282, 1995.
	LQ	Dunn et al., "Polystyrene-Poly (Ethylene Glycol) (PS-PEG2000) Particles as Model Systems for Site Specific Drug Delivery. 2. The Effect of PEG Surface Density on the <i>in Vitro</i> Cell Interaction and <i>in Vivo</i> Biodistribution," <i>Pharmaceutical Research</i> 11(7): 1016-1022, 1994.
	LR	Embelton and Tighe, "Polymers for Biodegradable medical devices. X. Microencapsulation studies: control of poly-hydroxybutyrate-hydroxyvalerate microcapsules porosity via polycaprolactone blending," <i>J. Microencapsulation</i> 10(3): 341-352, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	MA	5,588,962	12/31/96	Nicholas et al.	604	52	
	MB	5,593,683	01/14/97	Viegas et al.	424	427	
	MC	5,595,974	01/21/97	Tomaru	514	21	
	MD	5,597,798	01/28/97	Howell et al.	514	12	
	ME	5,599,307	02/04/97	Bacheer et al.	604	101	
	MF	5,599,335	02/04/97	Goldman et al,	604	368	
	MG	5,599,553	02/04/97	Chung	424	435	
	MH	5,599,820	02/04/97	Ojima et al.	514	320	
	MI	5,599,844	02/04/97	Grainger et al.	514	651	
	MJ	5,602,112	02/11/97	Rubinfeld	514	58	
	MK	5,605,702	02/25/97	Teillaud et al.	424	448	
	ML	5,607,418	03/04/97	Arzbaecher	604	891.1	
	MM	5,607,686	03/04/97	Totakura et al.	424	426	
	MN	5,609,574	03/11/97	Kaplan et al.	604	53	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	MO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	MP	Engelberg and Kohn, "Physico-mechanical properties of degradable polymers used in medical applications: a comparative study," <i>Biomaterials</i> 12: 292-304, 1991.
	MQ	Ettinger, "Overview of Paclitaxel (TAXOL®) in Advanced Lung Cancer," <i>Seminars in Oncology</i> 20(4 Suppl. 3): 46-49, August 1993.
	MR	Fernández-Ortiz et al., "A New Approach for Local Intravascular Drug Delivery (Iontophoretic Balloon)," <i>Circulation</i> 89(4): 1518-1522, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	NA	5,609,629	03/11/97	Fearnot et al.	623	1	
	NB	5,614,506	03/25/97	Falk et al.	514	54	
	NC	5,614,549	03/25/97	Greenwald et al.	514	449	
	ND	5,616,608	04/01/97	Kinsella et al.	514	449	
	NE	5,653,760	8/5/97	Saffran	623	11	
	NF	5,660,225	8/26/97	Saffran	623	16	
	NG	5,766,584	6/16/98	Edelman et al.	424	93.7	
	NH	5,886,026	3/23/99	Hunter et al.	514	449	
	NI	5,994,341	11/30/99	Hunter et al.	514	210	
	NJ	6,091,980	7/18/00	Squire et al.	600	381	
	NK	6,179,858	1/30/01	Squire et al.	606	198	
	NL	6,231,585	5/15/01	Takahashi et al.	606	191	
	NM	6,326,017	12/4/01	Mayberg	424	422	
	NN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	NO					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	NP	French et al., "Physicochemical aspects of controlled release of substituted benzoic and naphthoic acids from Carbopol [®] gels," <i>Journal of Controlled Release</i> 37: 281-289, 1995.
	NQ	Fukuzaki et al., "A New Biodegradable Pasty-Type Copolymer of L-Lactic Acid and δ-Valerolactone With Relatively Low Molecular Weight for Application in Drug Delivery Systems," <i>Journal of Controlled Release</i> 10: 293-303, 1989.
	NR	Fukuzaki et al., "In vivo characteristics of low molecular weight copolymers composed of L-Lactic acid and various DL-hydroxy acids as biodegradable carriers for drug delivery systems," <i>Biomaterials</i> 11: 441-446, 1990.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
OB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

OC	Gao et al., "Controlled Release of a Contraceptive Steroid from Biodegradable and Injectable Gel Formulations: <i>In Vitro</i> Evaluation," <i>Pharmaceutical Research</i> 12(6): 857-863, 1995.
OD	Gebelein et al., "The Release Of 5-Fluorouracil From Polycaprolactone Matrices," <i>Polym. Sci. Technol.</i> 38(Appl. Bioact. Polym. Mater.):151-163, 1988.
OE	Golomb et al., "Controlled delivery of a tryphostin inhibits hyperplasia in a rat cartoid artery injury model," <i>Atherosclerosis</i> 125: 171-182, 1996.
OF	Golomb et al., <i>Encyclopedic handbook of biomaterials and bioengineering, Part B: Applications, Vol. 1 and 2</i> , Wise et al. (eds.), Marcel Dekker, Inc., New York, NY, USA; Basel, Switzerland, 1995, Chapter 37, "Perivascular Polymeric Controlled-Release Therapy," pp. 1043-1055.
OG	Gonschior et al., "A new catheter for prolonged local drug application," <i>Coronary Artery Disease</i> 6:329-334, 1995.
OH	Gonschior et al., "Comparison of local intravascular drug-delivery catheter systems," <i>Am Heart J</i> 130(6): 1174-1181, 1995.
OI	Grijpma et al., "Star-shaped polylactide-containing block copolymers," <i>Makromol. Chem. Rapid Commun.</i> 14: 155-161, 1993.
OJ	Grosvenor and Staniforth, "The effect of Molecular weight on the rheological and tensile properties of Poly(ϵ -caprolactone)," <i>International Journal of Pharmaceutics</i> 135: 103-109, 1996.
OK	Gu et al., "Biodegradable block copolymer matrices for long-acting contraceptives with constant release," <i>Journal of Controlled Release</i> 22: 3-14, 1992.
OL	Gutowska et al., "Heparin release from the thermosensitive hydrogels," <i>Journal of Controlled Release</i> 22: 95-104, 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
PB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

PC	Harada et al., "Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts," <i>J. Clin. Invest.</i> 94: 623-630, 1994.
PD	Harland and Peppas, "Hydrophilic/hydrophobic, block and graft copolymeric hydrogels: synthesis, characterization, and solute partition and penetration," <i>Journal of Controlled Release</i> 26: 157-174, 1993.
PE	Harsh and Gehrke, "Controlling the swelling characteristics of temperature-sensitive cellulose ether hydrogels," <i>Journal of Controlled Release</i> 17: 175-186, 1991.
PF	Hekmat, E., "Fatal Myocardial Infarction Potentially Induced By Paclitaxel," <i>Ann Pharmacother</i> 30: 1110-1112, 1996.
PG	Heller et al., "The Sustained Release of Galardin and Taxol from Gelatin Chondroitin Sulfate Coacervate Films," <i>Mat. Res. Soc. Symp. Proc.</i> 394: 55-60, 1995.
PH	Hoffman et al., "Characterization pore Sizes and Water "Structure" in Stimuli-Responsive Hydrogels," <i>Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem.)</i> 34(1): 828, 1993.
PI	Hoffman, "Applications of Thermally Reversible Polymers and Hydrogels in Therapeutics and Diagnostics," at <i>Third International Symposium on Recent Advances in Drug Delivery Systems</i> , Salt Lake City, UT, February 24-27, 1987, pp. 297-305.
PJ	Hoffman, "Thermally Reversible Hydrogels Containing Biologically Active Species," <i>Polymers in Medicine III</i> , C. Migliares et al. (eds.), Elsevier Science Publishers B. V., Amsterdam, pp. 161-167, 1988.
PK	Holland et al., "Polymers for Biodegradable Medical Devices. 1. The Potential of Polyesters as Controlled Macromolecular Release Systems," <i>Journal of Controlled Release</i> 4: 155-180, 1986.
PL	Hong et al., "The Effect of Porous Infusion Balloon-Delivered Angiopeptin on Myointimal Hyperplasia After Balloon Injury in the Rabbit," <i>Circulation</i> 88(2): 638-648, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
QA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
QB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

QC	Hu and Liu, "Effect of soft segment on degradation kinetics in polyethylene glycol/poly (L-lactide) block copolymers," <i>Polymer Bulletin</i> 30: 669-676, 1993.
QD	Hu and Liu, "Effects of soft segments and hydrolysis on the crystallization behavior of degradable poly (oxyethylene)/poly (L-lactide) block copolymers," <i>Macromol. Chem. Phys.</i> 195: 1213-1223, 1994.
QE	Huehns et al., "Adventia as a target for intravascular local drug delivery," <i>Am Heart J</i> 75: 537-538, 1996.
QF	Iwamiya et al., "Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system." <i>Cancer Chemother Pharmacol.</i> 33(Suppl.): S134-S138, 1994.
QG	Izuka et al., "Molecular weight dependence of viscoelasticity of polycaprolactone critical gels," <i>Macromolecules</i> 25(9): 2422-2428, 1992.
QH	Jampel et al., "Glaucoma Filtration Surgery in Nonhuman Primates Using Taxol and Etoposide in Polyanhydride Carriers," <i>Investigative Ophthalmology & Visual Science</i> 34(11): 3076-3083, 1993.
QI	Janarthanan et al., "Intramolecular Interactions in Poly(styrene-co-acrylonitrile)/Poly(ε-caprolactone) Blends," <i>Journal of Polymer Science:Part B:Polymer Physics</i> 31: 1013-1017, 1993.
QJ	Jedlinski et al., "Polymerization of lactones, 17 synthesis of ethylene glycol-L-lactide block copolymers," <i>Makromol. Chem.</i> 194(6): 1681-1689, 1993.
QK	Jianzhong et al., "Polycaprolactone-poly (ethylene glycol) block copolymer, III. Drug release behavior," <i>Chinese Journal of Polymer Science</i> 13(2): 154-161, 1995.
QL	Jin et al., "Lipobeads: a hydrogel anchored lipid vesicle system," <i>FEBS Letters</i> 397: 70-74, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	RA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	RB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	RC	Johnston et al., "Sustained Delivery of Interleukin-2 from a poloxamer 407 Gel Matrix Following Intraperitoneal Injection in Mice," <i>Pharmaceutical Research</i> 9(3): 425-433, 1992
	RD	Jones et al., "Phase II Study of Paclitaxel Therapy for Unrespectable Biliary Tree Carcinomas," <i>Journal of Clinical Oncology</i> 14(8): 2306-2310, 1996.
	RE	Katono et al., "Thermo-responsive swelling and drug release switching of interpenetrating polymer networks composed of poly (acrylamide-co-butyl methacrylate) and poly (acrylic acid)," <i>Journal of Controlled Release</i> 16: 215-228, 1991.
	RF	Kazanskii et al., Ionizable hydrogels of new type based on poly (ethylene glycol) phosphates," <i>Polymer Gels and Networks</i> 4: 335-349, 1996.
	RG	Kelsen et al., "A Phase II Trial of Paclitaxel (Taxol) in Advanced Esophageal Cancer: Preliminary Report," <i>Seminars in Oncology</i> 21(5): 44-48, 1994.
	RH	Kennedy et al., "Prevention of experimental postoperative peritoneal adhesions by N,O-carboxymethyl chitosan," <i>Surgery</i> 120(5): 866-870, 1996.
	RI	Kim et al., "Hydrogels: swelling, drug loading, and release," <i>Pharmaceutical Research</i> 9(3): 283-290, 1992.
	RJ	Kimura et al., "Preparation of block copoly (ester-ether) comprising poly (L-lactide) and poly (oxypropylene) and degradation of its fibre <i>in vitro</i> and <i>in vivo</i> ," <i>Polymer</i> 30(7): 1342-1349, 1989.
	RK	Koenig and Huang, "Biodegradable blends and composites of polycaprolactone and starch derivatives," <i>Polymer</i> 36(9): 1877-1882, 1995.
	RL	Kohler and Goldspiel, "Paclitaxel (Taxol)," <i>Pharmacotherapy</i> 14(1): 3-34, 1994.
	RM	Kono et al., "Temperature-sensitive liposomes: liposomes bearing poly (N-isopropylacrylamide)," <i>Journal of Controlled Release</i> 30: 69-75, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	SA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	SB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	SC	Krüger et al., "Elastic properties of thin ultraoriented poly (ϵ -caprolactone) films grown on PTFE substrates as revealed by brillouin spectroscopy," <i>Journal of Polymer Science: Part B: Polymer Physics</i> 30: 1173-1176, 1992.
	SD	Kumar and Himmelstein, "Modification of in Situ Gelling Behavior of Carbopol Solutions by Hydroxypropyl Methylcellulose," <i>Journal of Pharmaceutical Sciences</i> 84(3): 344-348, 1995.
	SE	Langer and Peppas, "Present and future applications of biomaterials in controlled drug delivery systems," <i>Biomaterials</i> 2:201-214, 1981.
	SF	Li and Feng, "Biodegradable polymeric matrix for long-acting and zero-order release drug delivery systems," <i>Makromol. Chem. Macromol. Symp.</i> 33:253-264, 1990.
	SG	Li et al., "Synthesis, characterization, and hydrolytic degradation of PLA/Peo?PLA triblock copolymers with long poly (L-lactic acid) blocks," <i>Macromolecules</i> 29:57-62, 1996.
	SH	Lovich and Edelman, "Mechanisms of Transmural Heparin Transport in the Rat Abdominal Aorta After Local Vascular Delivery," <i>Circulation Research</i> 77(6):1143-1150, 1995.
	SI	Lyatskaya and Birshtein, "Triblock copolymers: the role of interfacial tension coefficients at two interfaces," <i>Polymer</i> 36(5):975-980, 1995.
	SJ	March et al., "Biodegradable Microspheres Containing a Colchicine Analogue Inhibit DNA Synthesis in Vascular Smooth Muscle Cells," <i>Circulation</i> 89(5):1929-1933, 1994.
	SK	Martini et al., "The bioadhesive properties of a triblock copolymer of ϵ -caprolactone and ethylene oxide," <i>International Journal of Pharmaceutics</i> 113:223-229, 1995.
	SL	Martini et al., "The Release of 5-Fluorouracil from a Swellable Matrix of a Triblock Copolymer of ϵ -Caprolactone and Ethylene Oxide," <i>Pharmaceutical Research</i> 12(11): 1786-1790, 1995.
	SM	Matsuda et al., "Photoinduced prevention of tissue adhesion," <i>ASAIO Journal</i> 38:M154-M157, 1992.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
110129.405C3APPLICATION NO.
10/671,327

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

William L. Hunter et al.

FILING DATE

September 25, 2003

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	TA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	TB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	TC	Milas et al., "Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol," <i>Cancer Chemother. Pharmacol.</i> 35:297-303, 1995.
	TD	Miyamoto et al., "Polylactic Acid-Polyethylene Glycol Block Copolymer," <i>Clinical Orthopaedics and Related Research</i> 294:333-343, 1993.
	TE	Muller et al., "Intramural Methotrexate Therapy for the Prevention of Neointimal Thickening After Balloon Angioplasty," <i>JACC</i> 20(2):460-466, 1996.
	TF	Nakafuku and Sakoda, "Melting and crystallization of poly (L-lactic acid) and poly (ethylene oxide) binary mixture," <i>Polymer Journal</i> 25(9):909-917, 1993.
	TG	Nakayama and Matsuda, "Preparation and characteristics of photocrosslinkable hydrophilic polymer having cinnamate moiety," <i>Journal of Polymer Science: Part A: Polymer Chemistry</i> 30:2451-2457, 1992.
	TH	Nakayama and Matsuda, "Surface fixation of poly (ethylene glycol) via photodimerization of Cinnamate group," <i>Journal of Polymer Science: Part A: Polymer Chemistry</i> 31:3299-3305, 1993.
	TI	Nasser et al., "Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: Quantitation and localization by confocal scanning laser microscopy," <i>American Heart Journal</i> 131(5):892-898, 1996.
	TJ	Nojima et al., "Crystallization of Block Copolymers II. Morphological study of poly (ethylene glycol)-poly (ε-caprolactone) block copolymers," <i>Polymer Journal</i> 24(11):1271-1280, 1992.
	TK	Nojima et al., "Morphology formed in binary blends of poly (ε-caprolactone) and ε-caprolactone-butadiene diblock copolymer," <i>Polymer</i> 36(14):2853-2856, 1995.
	TL	Nomura et al., "Prediction of the Coding Sequences of Unidentified Human Genes. II. The Coding Sequences of 40 New Genes (KIAA0041-KIAA0080) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1," <i>DNA Research</i> 1:223-229, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 110129.405C3		APPLICATION NO. 10/671,327	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS William L. Hunter et al.			
				FILING DATE September 25, 2003		GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	UA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	UB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	UC	Okada et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," <i>Neurosurgery</i> 25(6):892-898, 1989.					
	UD	Okana et al., "Temperature-responsive poly (N-isopropylacrylamide) as a modulator for alteration of hydrophilic/hydrophobic surface properties to control activation/inactivation of platelets," <i>Journal of Controlled Release</i> 36:125-133, 1995.					
	UE	Okana, "Molecular Design of Stimuli-Responsive Hydrogels for Temporal Controlled Drug Delivery," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater</i> 22:111-112, 1995.					
	UF	Oliver et al., "Suppression of Collagen-Induced Arthritis Using and Angiogenesis Inhibitor, AGM-1470, and a Microtubule Stabilizer, Taxol," <i>Cellular Immunology</i> 157:291-299, 1994					
	UG	Osada and Ross-Murphy, "Intelligent Gels," <i>Scientific American</i> (May):82-97, 1993.					
	UH	Oudhuis et al., "A comparison between the morphology of semicrystalline polymer blends of poly(ε-caprolactone)/poly(vinyl methylether) and poly(ε-caprolactone)/(styrene-acrylonitrile)," <i>Polymer</i> 36(18):3936-3942, 1994.					
	UI	Paavola et al., "Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block," <i>Pharmaceutical Research</i> 12(12):1997-2002, 1995.					
	UJ	Palasis and Gehrke, "Permeability of responsive poly (N-isopropylacrylamide) gel to solutes," <i>Journal of Controlled Release</i> 18:1-12, 1992.					
	UK	Park et al., "Poly (L-lactic acid)/pluornic blends: characterization of phase separation behavior, degradation, and morphology and use as protein-releasing matrices," <i>Macromolecules</i> 25:116-122, 1992.					
	UL	Peng et al., "Role of polymers in improving the results of stenting in coronary arteries," <i>Biomaterials</i> 17:685-694, 1996.					
	UM	Peppas and Sahlin, "Hydrogels as mucoadhesive and bioadhesive materials: a review," <i>Biomaterials</i> 17:1553-1561, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 110129.405C3		APPLICATION NO. 10/671,327	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS William L. Hunter et al.			
				FILING DATE September 25, 2003		GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	VA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	VB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	VC	Perego et al., "Preparation of a new nerve guide from a poly(L-lactide-co-6-caprolactone)," <i>Biomaterials</i> 15(3):189-193, 1994.					
	VD	Pitt and Gu, "Modification of the rates of chain cleavage of poly(ε-caprolactone) and related polyesters in the solid state," <i>Journal of Controlled Release</i> 4:283-292, 1987.					
	VE	Pitt et al., "Aliphatic polyesters II. The degradation of poly (DL-lactide), poly (ε-caprolactone), and their copolymers <i>in vivo</i> ," <i>Biomaterials</i> 2:215-220, 1981.					
	VF	Pitt et al., "Biodegradable Drug Delivery Systems Based On Aliphatic Polyesters: Application To Contraceptives and Narcotic Antagonists," in Richard W. Baker (ed.), <i>Controlled Release Of Bioactive Materials</i> [Symp. Int. Meet. Controlled Release Soc.], Academic Press, Inc., New York, NY, 1980, pp.19-43.					
	VG	Pitt et al., "Blends of PVA and PGLA: control of the permeability and degradability of hydrogels by blending," <i>Journal of Controlled Release</i> 19:189-200, 1992.					
	VH	Pitt et al., "Sustained Drug Delivery Systems II: Factors Affecting Release Rates from Poly(ε-caprolactone) and Related Biodegradable Polyesters," <i>Journal of Pharmaceutical Sciences</i> 68(2):1534-1538, 1979.					
	VI	Pitt et al., "Sustained Drug Delivery Systems. I. The Permeability of Poly (ε-Caprolactone), Poly (DL-Lactic Acid), and Their Copolymers," <i>Journal of Biomedical Materials Research</i> 13:497-507, 1979.					
	VJ	Pitt et al., "The Enzymatic Surface Erosion of Aliphatic Polyesters," <i>Journal of Controlled Release</i> 1:3-14, 1984.					
	VK	Pitt, "Poly-ε-Caprolactone and Its Copolymers," in <i>Biodegradable Polymers as Drug Delivery Systems</i> , (Eds. Langen, R., and Chasin, M), Marcel Dekker, New York, NY, pp 71-120, 1990.					
	VL	Ranucci and Ferruti, "High swelling gels for sensing applications," <i>Macromol. Symp.</i> 109: 89-103, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	WA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	WB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	WC	Rashkov et al., "Synthesis, characterization, and hydrolytic degradation of PLA/PEO/PLA triblock copolymers with short poly (L-lactic acid) chains," <i>Macromolecules</i> 29:50-56, 1996.
	WD	Riessen and Isner, "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies," <i>JACC</i> 23(5): 1234-1244, 1994.
	WE	Rim and Runt, "Melting Behavior of Crystalline/Compatible Polymer Blends: Poly(ε-caprolactone)/Poly(styrene-co-acrylonitrile)," <i>Macromolecules</i> 16(5):763-768, 1983.
	WF	Rowinsky and Donehower, "Paclitaxel (Taxol)," <i>The New England Journal of Medicine</i> 332(15):1004-1014, 1995.
	WG	Rowinsky and Donehower, "Taxol: Twenty Years Later, the Story Unfolds," <i>Journal of the National Cancer Institute</i> 83(24):1778-1781, 1991.
	WH	Rowinsky et al., "Clinical Toxicities Encountered With Paclitaxel (Taxol®)," <i>Seminars in Oncology</i> 20(4 Suppl. 3):1-15, 1993.
	WI	Rowinsky et al., "Taxol: A Novel Investigation Antimicrotubule Agent," <i>J. Natl. Cancer Inst.</i> 82(15):1247-1259, 1990.
	WJ	Rowinsky et al., "Taxol: The First of the Taxanes, an Important New Class of Antitumor Agents," <i>Seminars in Oncology</i> 19(6):646-662, 1992.
	WK	Sauro et al., "The Anti-Tumor Agent, Taxol, Attenuates Contractile Activity In Rat Aortic Smooth Muscle," <i>Life Sciences</i> 56(7):157-161, 1995.
	WL	Sawhney and Hubbell, "Rapidly degraded terpolymers of dl-lactide, glycolide, and ε-caprolactone with increased hydrophilicity by copolymerization with polyethers," <i>Journal of Biomedical Materials Research</i> 24:1397-1411, 1990.
	WM	Shah et al., "A biodegradable injectable implant for delivering micro and macromolecules using poly(lactic-co-glycolic) acid (PLGA) copolymers," <i>Journal of Controlled Release</i> 27: 139-147, 1993.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 110129.405C3		APPLICATION NO. 10/671,327	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS William L. Hunter et al.			
				FILING DATE September 25, 2003		GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	XA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	XB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	XC	Sharma and Straubinger, "Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes," <i>Pharmaceutical Research</i> 11(6):889-896, 1994.					
	XD	Sharma et al., "Antitumor Effect of Taxol-containing Liposomes in a Taxol-resistant Murine Tumor Model," <i>Cancer Research</i> 53:5877-5881, 1993.					
	XE	Sharma et al., "Antitumor Efficacy of Taxane Liposomes on a Human Ovarian Tumor Xenograft in Nude Athymic Mice," <i>Journal of Pharmaceutical Sciences</i> 84(12):1400-1404, 1995.					
	XF	Sharma et al., "Novel Taxol [®] Formulation: Polyvinylpyrrolidone Nanoparticle-Encapsulated Taxol [®] for Drug Delivery in Cancer Therapy," <i>Oncology Research</i> 8(7/8):281-286, 1996.					
	XG	Sharma et al., "Pharmaceutical and Physical Properties of Paclitaxel (Taxol) Complexes with Cyclodextrins," <i>Journal of Pharmaceutical Sciences</i> 84(10):1223-1230, 1995.					
	XH	Shen-Guo and Bo, "Polycaprolactone-poly(ethylene glycol) block copolymer, I: Synthesis and Degradability <i>in vitro</i> ," <i>Polymers for Advanced Technologies</i> 4:363-366, 1993.					
	XI	Shen-Guo et al., "Polycaprolactone-poly (ethylene glycol) block copolymer, II. Relationship among composition, crystallinity and degradability," <i>Acta Polymeric Sinica</i> 5:560-565, 1995 (+ English Abstract on page 565).					
	XJ	Shi et al., "Transcatheter Delivery of <i>c-myc</i> Antisense Oligomers Reduces Neointimal Formation in a Porcine Model of Coronary Artery Balloon Injury," <i>Circulation</i> 90(2):944-951, 1994.					
	XK	Shively et al., "Physico-chemical characterization of polymeric injectable implant delivery system," <i>Journal of Controlled Release</i> 33:237-243, 1995.					
	XL	Smetana Jr. et al., "Influence of intraperitoneal injection of three types of hydrogel beads on expression of carbohydrate-binding sites in spleen macrophages," <i>Biomaterials</i> 17(24):2335-2341, 1996.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 110129.405C3		APPLICATION NO. 10/671,327	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS William L. Hunter et al.			
				FILING DATE September 25, 2003		GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	YA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	YB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	YC	Sollott et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," <i>J. Clin. Invest.</i> 95:1869-1876, 1995.					
	YD	Spencer and Faulds, "Paclitex. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Cancer," <i>Drugs</i> 48(5):795-847, 1994.					
	YE	Tarr et al., "A New Parenteral Emulsion for the Administration of Taxol," <i>Pharmaceutical Research</i> 4(2):162-165, 1987.					
	YF	Thomas et al., "Local intracoronary heparin delivery with a microporous balloon catheter," <i>Am. Heart J.</i> 132(5):969-972, 1996.					
	YG	Trigo et al., "Anticancer drug, ara-C, release from pHEMA hydrogels," <i>Biomaterials</i> 15(14):1181-1186, 1994.					
	YH	Tsitsilianis et al., "Amphiphilic heteroarm star copolymers of polystyrene and poly (ethylene oxide)," <i>Polymer</i> 36(19):3745-3752, 1995.					
	YI	Tung, "Rheological behavior of poloxamer 407 aqueous solutions during sol-gel and dehydration processes," <i>International Journal of Pharmaceutics</i> 107:85-90, 1994.					
	YJ	Ulbrich et al., "Synthesis of novel hydrolytically degradable hydrogels for controlled drug release," <i>Journal of Controlled Release</i> 34:155-165, 1995.					
	YK	Van den Mooter et al., "The Relation Between Swelling Properties and Enzymatic Degradation of Azo Polymers Designed for Colon-Specific Drug Delivery," <i>Pharm. Res.</i> 11(12):1737-1741, 1994.					
	YL	Villa et al., "Local Delivery of Dexamethasone for Prevention of Neointimal Proliferation in a Rat Model of Balloon Angioplasty," <i>J. Clin. Invest.</i> 93: 1243-1249, 1994.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 110129.405C3		APPLICATION NO. 10/671,327	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS William L. Hunter et al.			
				FILING DATE September 25, 2003		GROUP ART UNIT 1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	ZA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION	
						YES	NO
	ZB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	ZC	Violante and Lanzafame, "Cremaphor-free Paclitaxel Formulation," <i>Proceedings of the American Association for Cancer Research Annual Meeting Volume 36</i> : Abstract No. 1841, 1995.					
	ZD	Wada et al., "in Vitro Evaluation of Sustained Drug Release from Biodegradable Elastomer," <i>Pharmaceutical Research</i> 8(10):1292-1295, 1991.					
	ZE	Walter et al., "Interstitial Taxol Delivered from a Biodegradable Polymer Implant against Experimental Malignant Glioma," <i>Cancer Research</i> 54:2207-2212, 1994.					
	ZF	Wang et al., "Preparation and Characterization of Poly(lactic-co-glycolic acid) Microspheres for Targeted Delivery of a Novel Anticancer Agent, Taxol," <i>Chem. Pharm. Bull</i> 44(10): 1935-1940, 1996.					
	ZG	Wilensky et al., "Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplasty," <i>Am. Heart J.</i> 122(Vol. 4)(Part 1):1136-1140, 1991.					
	ZH	Wilensky et al., "Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters," <i>American Heart Journal</i> 129(5):852-859, 1995.					
	ZI	Winternitz et al., "Development of a Polymeric Surgical Paste Formulation for Taxol," <i>Pharmaceutical Research</i> 13(3):368-375, 1996.					
	ZJ	Wolinsky et al., "Use of a Perforated Balloon Catheter to Deliver Concentrated Heparin Into the Wall of the Normal Canine Artery," <i>JACC</i> 15(2):475-481, 1990.					
	ZK	Woodward et al., "The intracellular degradation of poly(ε-caprolactone)," <i>Journal of Biomedical Materials Research</i> 19:437-444, 1985.					
	ZL	Yang et al., "Structures of oxyethylene/oxybutylene diblock copolymers in their solid and liquid states," <i>Macromolecules</i> 28:6029-6041, 1995.					
	ZM	Yasurmori et al., "Placement of covered self-expanding metallic stents in the common bile duct: A feasibility study," <i>Journal of Vascular and Interventional Radiology</i> November-December:773-778, 1993.					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 110129.405C3	APPLICATION NO. 10/671,327
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS William L. Hunter et al.	
		FILING DATE September 25, 2003	GROUP ART UNIT 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AAA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
AAB					

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AAC	Ye and Chien, "Dual-controlled drug delivery across biodegradable copolymer. II. Delivery kinetics of levonorgestrel and estradiol from (matrix/matrix) laminate drug delivery system," <i>Journal of Controlled Release</i> 41:259-269, 1996.
AAD	Yoshida et al., "Positive thermosensitive pulsatile drug release using negative thermosensitive hydrogels," <i>Journal of Controlled Release</i> 32:97-102, 1994.
AAE	Youxin and Kissel, "Synthesis and properties of biodegradable ABA triblock copolymers consisting of poly (L-lactic acid) or poly (L-lactic-co-glycolic acid) A-blocks attached to central poly (oxyethylene) B-blocks," <i>Journal of Controlled Release</i> 27:247-257, 1993.
AAF	Youxin et al., "In-vitro degradation and bovine serum albumin release of the ABA triblock copolymers consisting of poly (L(+))lactic acid, or poly (L(+))lactic acid-co-glycolic acid) A-blocks attached to central polyoxyethylene B-blocks," <i>Journal of Controlled Release</i> 32:121-128, 1994.
AAG	Yu and Grainger, "Novel thermo-sensitive amphiphilic gels: poly N-isopropylacrylamide-co-sodium acrylate-co-n-N-alkylacrylamide network synthesis and physicochemical characterization," at <i>Sixth International Symposium on Recent Advances in Drug Delivery Systems</i> , Salt Lake City, Utah, USA, February 21-24, 1993, pp. 820-821.
AAH	Yu and Grainger, "Thermo-sensitive swelling behavior in crosslinked N-isopropylacrylamide networks: cationic, anionic and ampholytic hydrogels," <i>Polym. Prepr.</i> 34(1):829-830, 1993.
AAI	Zhou and Smid, "Physical hydrogels of associative star polymers," <i>Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem)</i> 34(1): 822-823, 1993.
AAJ	Zhu et al., "Preparation, characterization, and properties of polylactide (PLA)-poly (ethylene glycol) (PEG) copolymers: a potential drug carrier," <i>Journal of Applied Polymer Science</i> 39:1-9, 1990.
AAK	Zhu et al., "Super microcapsules (SMC). I. Preparation and characterization of star polyethylene oxide (PEO)-polyactide (PLA) copolymers," <i>Journal of Polymer Science: Part A: Polymer Chemistry</i> 27:2151-2159, 1989.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).